Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2006

View Archived Issues

MORAb-009 enters clinical development for mesothelin-expressing tumors

Fentanyl Taifun shows efficacy in breakthrough cancer pain

Disappointing phase IIb results for VLTS-934

New phase II study for Lymphoseek

CeNeS reports recent pipeline progress

MED-205 shows cholesterol-lowering activity in cholesterol animal model

BioInvent to focus on back-up compounds to BI-201 in HIV

New venture funding to support Elusys Therapeutics' HP Antibody pipeline

FDA lifts clinical hold on GENASIS trial

Predix receives milestone from Cystic Fibrosis Foundation Therapeutics

SIGA-246 for smallpox completes initial safety clinical trial

RAID Pilot Program supports development of EPI-A0001 for Friedreich's ataxia

Cardeva cleared to begin clinical trials in U.S.

Schering AG will not exercise option for EP-2104R

EuroPharma reports on preliminary clinical data for Vectomega

End-of-phase II meeting scheduled for Polynoma-1

Taiho licenses rights for Meiji Dairies' agent for cedar pollen allergy

Pycnogenol more effective than Daflon in reducing edema and walking pain

Neuroprotective action of minocycline associated to PARP-1 inhibition

Amgen's calcium-sensing receptor agonist AMG-641 beneficial in hyperparathyroidism secondary to CKD

Anti-PDGF-D monoclonal antibody may help delay mesangioproliferative nephritis progression

Oral Posiphen markedly attenuates Abeta-42 in vivo

Novel antibody-independent nasal vaccination for AD

CNI-1493 facilitates dramatic reductions in Abeta and microglial activity in AD

New agents for arthritis claimed in recent patent literature

Recent patents describe novel therapeutic agents for respiratory disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...